Latest News for: psyence
Edit
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split
Nasdaq Globe Newswire 15 Jan 2026
Edit
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split (Form 6-K) (Psyence Biomedical Ltd)
Public Technologies 14 Jan 2026
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split. NEW YORK - January 14, 2026 - Psyence Biomedical Ltd ... About Psyence BioMed. Psyence Biomedical Ltd ... Contact Information for Psyence Biomedical Ltd ... Psyence Biomedical Ltd.
Edit
Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity (Form 6-K) (Psyence Biomedical Ltd)
Public Technologies 13 Jan 2026
Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity. NEW YORK - January 12, 2026 - Psyence Biomedical Ltd ... About Psyence BioMed. Psyence Biomedical Ltd ... Contact Information for Psyence Biomedical Ltd.
Edit
Amendment to Current Report by Foreign Issuer (Form 6-K/A) (Psyence Biomedical Ltd)
Public Technologies 13 Jan 2026
Psyence Biomedical Ltd ... NOTICE IS HEREBY GIVEN that an annual and special meeting (the "Meeting") of the shareholders ("Shareholders") of Psyence Biomedical Ltd ... The participation of its shareholders is very important to Psyence.
Edit
Psyence Biomedical Ltd Interim Financials – September 30 2025 (Psyence Biomedical Ltd)
Public Technologies 13 Jan 2026
Psyence Biomedical Ltd ... (USD $) PSYENCE BIOMEDICAL LTD ... Investment in Psyence Labs Ltd ... Fair value gain on investment in Psyence Labs Ltd ... Fair value gain on investment in Psyence Labs Ltd ... Investment in Psyence Labs Ltd ... Psyence Biomedical Ltd.
Edit
Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity (Psyence Biomedical Ltd)
Public Technologies 12 Jan 2026
). The text version of this document is not available ... Psyence Biomedical Ltd.
Edit
Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity
Nasdaq Globe Newswire 12 Jan 2026
Edit
Notice of Annual General and Special Meeting of Shareholders to be held on January 22, 2026 and Management Information Circular, including the Consolidated Financial Statements of the Company for the years ended March 31, 2025 and 2024, and the Unaudited Condensed Consolidated Financial Statements for the Three and Six Months Ended September 30, 2025 and 2024, and the Management Discussion and Analysis related thereto (Form 6-K) (Psyence Biomedical Ltd)
Public Technologies 08 Jan 2026
Edit
Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No ...
Nasdaq Globe Newswire 05 Jan 2026
05, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd.
Edit
Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial
Nasdaq Globe Newswire 19 Dec 2025
Edit
Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and ...
Nasdaq Globe Newswire 09 Dec 2025
Edit
Opinion: The Future of Human Longevity Will Be Transformational – And Nature May Hold the Key (Psyence Biomedical Ltd)
Public Technologies 28 Nov 2025
). That is where psychedelics enter the longevity dialogue ... This is why Psyence BioMed became the first publicly listed company to launch a dedicated psilocybin longevity research initiative ... It's about expanding human potential ... Psyence Biomedical Ltd.
Edit
Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program (Psyence Biomedical Ltd)
Public Technologies 25 Nov 2025
NEW YORK - November 25, 2025 - Psyence Biomedical Ltd ... The collaboration with Psyence BioMed enables us to rigorously investigate these mechanisms and generate evidence that could guide future human studies." ... Psyence Biomedical Ltd.
Edit
Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program
Nasdaq Globe Newswire 25 Nov 2025- 1
- 2
- Next page »